Ibinini bya IN10018 byagenewe ubuvuzi bw’ibanze mu Bushinwa: Kwibanda ku ndwara ya kanseri y’inkondo y’umura ya KRAS G12C+ ivanze na D-1553, igeragezwa ry’ubuvuzi rirakomeje ku ikoranabuhanga rigezweho ryo kurwanya kanseri​

Ku ya 11 Kanama, Ikigo cy’Igihugu gishinzwe Ibikoresho by’Ubuvuzi (CDE) cyagaragaje ko gukoresha ibinini bya IN10018 byatanzwe na InxMed kugira ngo bivurwe neza, bigamije guhuzwa na D-1553 kugira ngo bivure kanseri y’inkondo y’umura ya KRAS G12C yanduye mutation-positive colorectal cancer (CRC) yavuwe nibura inshuro ebyiri mbere.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Indangamuntu ya WeChat: 17801183037

Email：myimmnet@163.com

Ku bijyanye na Ifebemtinib (IN10018)

Ifebemtinib (IN10018) ni umuti muto ugabanya cyane FAK, utangwa mu kanwa, kandi utuma ingirabuzimafatizo nto zirwanya indwara, ukaba ufite uburyo bwinshi bwo kuvura. Mu buvuzi, wagaragaje uburyo bwo kuvura buhuza imiti ikoreshwa mu kuvura indwara zitandukanye, ndetse n'ubuvuzi bw'umubiri. Kugeza ubu, abarwayi barenga 600 bavuwe bafite umutekano mwiza kandi bihanganira indwara.

Mu nama ngarukamwaka ya ASCO yo mu 2025, yasohoye amakuru agezweho y’ubuvuzi yavuye mu igerageza rya kliniki ry’icyiciro cya Ib/II (NCT06166836; NCT05379946) kugira ngo harebwe imikorere n’umutekano wa ifebemtinib (IN10018), inhibitor ya oral focal adhesion kinase (FAK) ifatanyije na garsorasib (D-1533), inhibitor ya KRAS G12C yo mu kanwa, muri tumors zikomeye za KRAS G12C mutant.

Amakuru y’ubuvuzi yatanzwe mu nama ngarukamwaka ya ASCO yo mu 2025 (Incamake #8629 | Ikibaho cy’amatangazo #109) yari arimo ibyavuye mu matsinda abiri:

Amakuru ajyanye no gukomeza gukurikirana itsinda ry’abantu barwaye kanseri y’ibihaha ya KRAS G12C itanduye kanseri y’ibihaha (NSCLC) yo ku rwego rwa mbere, hatitawe ku miterere ya PD-L1, bahawe imiti ya ifebemtinib + garsorasib.

Itsinda ry’abarwayi ba KRAS G12C-mutant colorectal cancer (CRC) bavuwe mbere bagereranya ifebemtinib+ garsorasib na garsorasib monotherapy.

Mu itsinda rya NSCLC, guhuza ifebemtinib na garsorasib, nk'uburyo bwo kunywa bubiri, budafite imiti igabanya ubukana bwa kanseri, byagaragaje inyungu zikomeye mu buvuzi harimo ubwiyongere bw'ingaruka no kuramba, hatitawe ku mikorere ya PD-L1, kandi mu itsinda rya CRC, ibyavuye mu bushakashatsi byagaragaje ko ifebemtinib ifite akamaro gakomeye ugereranije na KRAS inhibitor monotherapy.

Ingingo z'ingenzi muri NSCLC yo mu cyiciro cya mbere: Uburyo bwo kuvura hakoreshejwe uburyo bubiri bwo mu kanwa bugaragaza imikorere irambye n'inyungu zo kurokoka vuba

Kugeza ku ya 31 Werurwe 2025, abarwayi 33 ba mbere ba NSCLC, hatitawe ku mikorere ya PD-L1, biyandikishije kandi bahabwa imvange ya ifebemtinib na garsorasib, hamwe n'ikurikirana ry'amezi 16.0. Mbere iyi sosiyete yagaragaje igipimo cya Objective Response (ORR) cya 90.3% (amakuru yagaragajwe muri ESMO 2024). Amakuru yakurikiranywe ubu yavuzwe muri make ku buryo bukurikira:

Kurokoka hagati y’igihe nta guhindagurika kw’umubiri (mPFS): amezi 22.3

Igihe giciriritse cy'igisubizo DOR (mDOR): amezi 19.4

Imiterere rusange y'ubuzima (mOS): itaragerwaho, ifite imiterere ikomeye yo kubaho irushaho kuzamurwa no kugororoka igaragaza inyungu irambye.

Icyitonderwa, uburyo bwo kuvura bwagaragaje ko bufite akamaro gahoraho hatitawe ku miterere ya PD-L1.

Ibyavumbuwe by'ingenzi muri CRC yavuwe mbere: Igerageza ryihariye ryemeza ubufatanye na KRAS G12Ci

Ku itariki ya 21 Mata 2025, abarwayi 36 ba CRC bavuwe mbere bakorewe ku buryo butaziguye 1:1 kugira ngo bahabwe imvange ya ifebemtinib + garsorasib cyangwa garsorasib yonyine. Abarwayi bose basuzumwe hifashishijwe imirasire y'izuba kandi ibisubizo byo kurwanya ikibyimba byasuzumwe kandi muri make bikurikira:

ORR: 44.4% (itsinda rihuza) ugereranije na 16.7% (itsinda rimwe)

Igipimo cyo kurwanya indwara (DCR): 100.0% (combo) ugereranije na 77.8% (mono)

mPFS: amezi 7.7 (itsinda) ugereranije n'amezi 4.0 (itsinda rimwe)

mOS: itaragera ku ruhande rw'ukuboko; gutandukana hakiri kare byagaragaye mu mirongo yo kubaho

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Indangamuntu ya WeChat: 17801183037

Email：myimmnet@163.com